Device Trial Radar · NCT06699160
Refobacin Revision-3 Bone Cement Post-Market Study
Last checked: Nov 20, 2026Latest source record: Nov 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Aug 2025
Primary completion
Dec 2030
Study completion Dec 2030
Sponsor
- Lead sponsor
- Zimmer BiometPublic (ZBH)
- Sponsor type
- Industry
- First posted
- Nov 21, 2024
Design
- Study type
- Observational
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this post-market study is to confirm the safety, performance and clinical benefits of the Refobacin Revision-3 Bone Cement when used in knee or hip revision surgeries. This will be done by collecting information on: * removal of any metal components of the hip or knee implants used in combination with the cement * frequency and incidence of adverse events * overall pain and functional performance, subject quality of life, and radiographic parameters
Conditions
- Revision Arthroplasty
Interventions
Revision arthroplastyDevice
Hip or knee revision surgery resulting from aseptic loosening of the prosthesis and/or infection of the prosthesis by gentamicin and/or clindamycin sensitive strains.
Primary outcomes
What the sponsor says the trial is designed to measure.
- SurvivorshipTime frame: 3, 5 and 10 years post-operatively
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Diakonessenhuis UMC Utrecht
Utrecht, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.